Bristol Myers Squibb Co. BMY reported a net income of $2.262 Billion, or $1.07 per share, for the quarter ending March 31, up from $1.278 Billion, or 59 Cents a Share, the same period last year. The adjusted earnings per share came in at $2.05, which was higher than the $1.97 FactSet consensus. The revenue fell by 3%, from $11.648 to $11.337 Billion. This was below the $11.496 Billion FactSet consensus. Revlimid generic erosion, and a strong dollar, were the main reasons for revenue decline. Revlimid sales, which treat multiple myeloma, dropped by 24%, to $1.541 Billion. The company still expects a 2% revenue increase for the full year, but has raised its EPS forecast to a range between…